Document is current
Any future updates will be listed below
-
Authors
Sicklick, Jason K. https://orcid.org/0000-0003-4403-0271
Kato, Shumei
Okamura, Ryosuke
Patel, Hitendra
Nikanjam, Mina
Fanta, Paul T.
Hahn, Michael E.
De, Pradip
Williams, Casey
Guido, Jessica
Solomon, Benjamin M.
McKay, Rana R.
Krie, Amy
Boles, Sarah G.
Ross, Jeffrey S.
Lee, J. Jack
Leyland-Jones, Brian
Lippman, Scott M.
Kurzrock, Razelle
-
Funding
Funding for this research was provided by:
U.S. Food and Drug Administration (R01 FD006334)
- License Information
-
More Information
Article History
Received: 22 January 2021
Accepted: 15 September 2021
First Online: 4 October 2021
Declarations
:
: This study received ethics approval from the UC San Diego Human Research Protections Program (HRPP)’s Oncology Institutional Review Board (IRB-O) (Project 141758) and the Avera Cancer Institute’s Institutional Review Board (IRB00010096). This study complied with principles of the Helsinki Declaration. All participants provided written informed consent to the Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) study (groups 1 and 2), as well as separate written informed consent for any investigational drug trials to which they were navigated, per the two Institutional Review Board’s approval guidelines.
: Not applicable.
: J.K.S receives research funding from Amgen Pharmaceuticals and Foundation Medicine, consultant fees from Deciphera, speaker’s fees from Deciphera, Foundation Medicine, La-Hoffman Roche, Merck, MJH Life Sciences, QED Therapeutics, and has stock in Personalis. SK serves as a consultant to Foundation Medicine and receives speaker’s fee from Roche. RK has the following disclosure information: Stock and Other Equity Interests (IDbyDNA, CureMatch, Inc., and Soluventis); Consulting or Advisory role (Gaido, Loxo, X-Biotech, Actuate Therapeutics, Roche, NeoMed, Soluventis, and Pfizer); Speaker’s fee (Roche); Research Funding (Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, Konica Minolta, DeBiopharm, Boerhringer Ingelheim, and OmniSeq [All institutional]); Board Member (CureMatch, Inc and CureMetrix Inc). BS received travel funds from AstraZeneca. RRM receives institutional research funding from Bayer and Pfizer, as well as consultant fees from Bayer, Bristol Meyers Squib, Dendreon, Exelixis, Johnson & Johnson, Novartis, Pfizer, Sanofi, Vividion, and Tempus. JSR is an employee and equity holder in Foundation Medicine, Inc. The remaining authors declare that they have no competing interests.
